Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

计划入组 66 人 · 首次发布于 2024 年 4 月 3 日

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

计划入组 24 人 · 首次发布于 2024 年 1 月 17 日

A Phase 1 SAD/MAD Study of RLS-0071 in Healthy Volunteers in Support of a COVID-19 Development Program

计划入组 56 人 · 首次发布于 2022 年 3 月 28 日

RLS-1496

RLS-0088

RLS RX1

Riverbend Logistics Solutions, Inc.

United States

PRECISION DERMATOLOGY, INC.

United States

SLS FRANCE

France

Patrys Initiates Manufacturing and FDA Engagement for Injectable Delirium Treatment RLS-2201

ReAlta Life Sciences Doses First Patient in Phase 2 aGvHD Trial with RLS-0071

Rubedo Life Sciences Reports Positive Phase 1 Results for First-in-Class GPX4 Modulator RLS-1496 in Dermatological Conditions